The inhibition of CDK4/6 by palbociclib has been implicated in the activation of AKT and the mTOR pathway resulting in activation of cell proliferation, conferring resistance in Rb‐positive BC.129, 130. The gene discussed is CDK4; the disease is breast cancer.